CL

Chris Leahy

Senior Vice President Finance at Piramal Pharma Solutions

Chris Leahy has an extensive work experience in the pharmaceutical industry. Chris started their career at Pfizer UK Ltd in 2000, where they held roles such as Finance Team Lead / Director and Business Analysis Manager. Chris was responsible for all financial aspects of the Pfizer Pharmaceutical Facility in Morpeth, UK, including accounting, analysis and reporting, capital expenditure, accounts payable/receivable, and payroll. Chris later joined Piramal Healthcare UK Ltd in 2006 as Finance Director. In 2013, they moved to Piramal Enterprises Ltd as Finance Director for their Formulations Division. Currently, they are serving as the Senior Vice President of Finance at Piramal Pharma Solutions since 2017.

Chris Leahy obtained a Bachelor of Science (B.Sc.) degree in Mathematics from the University of Bristol between 1990 and 1993. Prior to attending the university, Chris attended Richmond School, although no specific details regarding degree or field of study were provided.

Location

Tamworth, United Kingdom

Links


Org chart


Teams


Offices

This person is not in any offices


Piramal Pharma Solutions

3 followers

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products & services, and potent solid oral drug product. Our track record as a trusted service provider with experience across varied technologies makes us a partner of choice for innovator and generic companies worldwide.